Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Shares Outstanding (Diluted Average): 2019-2023

Historic Shares Outstanding (Diluted Average) for CytomX Therapeutics (CTMX) over the last 5 years, with Dec 2023 value amounting to $73.8 million.

  • CytomX Therapeutics' Shares Outstanding (Diluted Average) rose 12.27% to $73.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was $73.8 million, marking a year-over-year increase of 12.27%. This contributed to the annual value of $73.8 million for FY2023, which is 12.27% up from last year.
  • Latest data reveals that CytomX Therapeutics reported Shares Outstanding (Diluted Average) of $73.8 million as of FY2023, which was up 12.27% from $65.7 million recorded in FY2022.
  • CytomX Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $73.8 million for FY2023, and its period low was $45.3 million during FY2019.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $68.3 million, with a median of $65.7 million in 2022.
  • Data for CytomX Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 40.12% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows CytomX Therapeutics' Shares Outstanding (Diluted Average) stood at $45.3 million in 2019, then grew by 2.79% to $46.6 million in 2020, then surged by 40.12% to $65.3 million in 2021, then grew by 0.68% to $65.7 million in 2022, then climbed by 12.27% to $73.8 million in 2023.